Burnaby, Canada

Paul Charifson

This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Xenon Pharmaceuticals Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul Charifson: Innovator in Sodium Channel Activators

Introduction

Paul Charifson is a notable inventor based in Burnaby, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sodium channel activators. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Paul Charifson holds a patent for "Pyridine derivatives and their use as sodium channel activators." This patent is directed to compounds of formula (1), which are designed to enhance the functionality of sodium channels. His work in this area is crucial for developing new therapeutic options for various medical conditions.

Career Highlights

Charifson is currently associated with Xenon Pharmaceuticals Inc., where he continues to push the boundaries of pharmaceutical research. His role at the company allows him to collaborate with other talented professionals in the industry, further enhancing his contributions to innovation.

Collaborations

Some of his notable coworkers include Verner Alexander Lofstrand and Jung Yun Kim. Their collective expertise fosters a dynamic environment for research and development, leading to groundbreaking advancements in their field.

Conclusion

Paul Charifson is a distinguished inventor whose work in sodium channel activators has the potential to impact the pharmaceutical industry significantly. His dedication to innovation and collaboration with esteemed colleagues positions him as a key figure in advancing medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…